Ensysce Biosciences (ENSC) EBIAT (2020 - 2025)
Ensysce Biosciences (ENSC) has disclosed EBIAT for 6 consecutive years, with -$3.7 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 663.51% to -$3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.0 million, a 38.42% decrease, with the full-year FY2024 number at -$8.0 million, up 24.84% from a year prior.
- EBIAT was -$3.7 million for Q3 2025 at Ensysce Biosciences, down from -$1.7 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $661769.0 in Q3 2024 to a low of -$17.2 million in Q3 2021.
- A 5-year average of -$4.2 million and a median of -$2.7 million in 2023 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 274889.7% in 2021, then soared 124.59% in 2024.
- Ensysce Biosciences' EBIAT stood at -$10.0 million in 2021, then surged by 45.42% to -$5.5 million in 2022, then surged by 36.03% to -$3.5 million in 2023, then fell by 1.71% to -$3.6 million in 2024, then decreased by 4.62% to -$3.7 million in 2025.
- Per Business Quant, the three most recent readings for ENSC's EBIAT are -$3.7 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.9 million (Q1 2025).